How is the EpiPen outrage impacting families, parents and children who need these products as protection against fatal allergy attacks? CNBC's Kate Kelly and Sue Herera discuss how its affecting their own children.
Tim Chiang, BTIG managing director, shares his take on Mylan, admid the EpiPen price outrage.
The "FMHR" traders; Sarat Sethi, Douglas C. Lane & Associates; and Stephanie Link, TIAA Global Asset Management, reveal their final trades, including CVS, Square and more.
Alex Tarrant, assistant editor at Dealreporter Europe, Mergermarket Group, shares his views on the deal between Pfizer and Medivation.
Iowa Senator Chuck Grassley sends a letter to Mylan CEO Heather Bresch about EpiPen pricing. CNBC's Meg Tirrell reports.
As biotech stocks rally, Chad Morganlander, Stifel Nicolaus, and Jonathan Krinsky, MKM Partners, share their take on the biotech sector.
CNBC's Meg Tirrell discusses the latest healthcare mergers and acquisitions.
Pfizer buys Medivation for $14 billion in cash. CNBC's Meg Tirrell reports the latest.
Shares of Mylan are under pressure as word spreads about the increased price of its EpiPen drug by 500 percent. David Maris, Wells Fargo managing director, shares his take.
The FDA approves two transcatheter heart valves manufactured by Edwards Lifesciences, CNBC's Seema Mody reports.
CNBC's Seema Mody reports the latest on Monsanto, including the company only giving Bayer selective access to confidential information.
CNBC's Brian Sullivan discusses three stocks he deems most interesting.
Earnings are out for Nvidia and Planet Fitness. CNBC's Susan Li reports the details for both companies.
Peder Holk Nielsen, Novozymes CEO, explains why economic uncertainty has caused the company to lower its earning guidance.
CNBC's Kate Kelly reports the latest details on Bill Ackman's Valeant stake.
Shares of Valeant surge as the company affirms forward guidance. CNBC's Meg Tirrell reports the details, including what CEO Joseph C. Papa has to say.
Shares of Bristol-Myers Squibb briefly fell more than 17 percent in opening trade Friday after its cancer drug failed to meet targets in a late-stage study.
Shares of Bristol Myers Squibb are way down today while shares of Merck are up. Here's why, and what's next, with Tony Butler, Guggenheim Securities.
While Bristol Myers Squibb is having its worst day in nearly 16 years, shares of Merck is up 5 percent year over year. Nancy Tengler, Heartland Financial, discusses one of her largest holdings.
Bristol Myers Squibb is having its worst day in nearly 16 years after failing to meet goals for a lung cancer drug. Alex Arfaei, BMO, discusses.